Research programme: liver X receptor modulators - Karo Pharma/Pfizer

Drug Profile

Research programme: liver X receptor modulators - Karo Pharma/Pfizer

Alternative Names: WAY-252623; WAY-254011; WYE-672

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karo Bio
  • Developer Pfizer
  • Class Indazoles; Quinolines
  • Mechanism of Action Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Inflammation

Most Recent Events

  • 17 Jul 2012 Due for review, but nothing appears to have changed so just did a quick check. No further publications on google, nothing in Pfizer website but still listed as late research/early preclin for inflammation on Karo website so left dev as is, and added active statement.
  • 01 Jun 2012 Development is ongoing for Inflammation in USA
  • 10 Sep 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top